GR270773 has not yet been approved in the US, EU or Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


GR270773 studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
EMD20001 (28-day Primary Analysis Phase) DEVELOPMENT TERMINATED BY GSK II A Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of the Safety and Efficacy of Three Days of Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-Negative Severe Sepsis in Adults
EMD20001 DEVELOPMENT TERMINATED BY GSK II Long-Term Mortality and Health Outcomes Results from a Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of the Safety and Efficacy of Three Days of Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-Negative Severe Sepsis in Adults